Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing ...
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including business acquisition news from Sun Pharma and Labcorp as well as new research from the National ...
Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing therapy rocatinlimab in atopic dermatitis (AD). The 24-week IGNITE study, which ...
Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.
Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...
Kyowa Kirin, Amgen’s rocatinlimab ignites positive response in Rocket study Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s ...
Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual ...
Dow Jones member Verizon is climbing despite the overall market correction. Amgen's weight loss drug is helping it to outperform the broad market. The NASDAQ opened more than 2% lower on Monday ...
placebo. Also Read: Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials In addition, IGNITE met the endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results